VOTRIENT Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Votrient, and what generic alternatives are available?
Votrient is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in VOTRIENT is pazopanib hydrochloride. There are five drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the pazopanib hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Votrient
A generic version of VOTRIENT was approved as pazopanib hydrochloride by APOTEX on October 19th, 2023.
Summary for VOTRIENT
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 102 |
Clinical Trials: | 103 |
Patent Applications: | 704 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for VOTRIENT |
What excipients (inactive ingredients) are in VOTRIENT? | VOTRIENT excipients list |
DailyMed Link: | VOTRIENT at DailyMed |
Recent Clinical Trials for VOTRIENT
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
National Cancer Institute, France | Phase 1/Phase 2 |
Centre Leon Berard | Phase 1/Phase 2 |
medac GmbH | Phase 2 |
Pharmacology for VOTRIENT
Drug Class | Kinase Inhibitor |
Mechanism of Action | Cytochrome P450 2C8 Inhibitors Cytochrome P450 2D6 Inhibitors Cytochrome P450 3A4 Inhibitors Protein Kinase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for VOTRIENT
US Patents and Regulatory Information for VOTRIENT
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-001 | Oct 19, 2009 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Novartis | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-002 | Oct 19, 2009 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VOTRIENT
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novartis | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-001 | Oct 19, 2009 | ⤷ Try a Trial | ⤷ Try a Trial |
Novartis | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-001 | Oct 19, 2009 | ⤷ Try a Trial | ⤷ Try a Trial |
Novartis | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-002 | Oct 19, 2009 | ⤷ Try a Trial | ⤷ Try a Trial |
Novartis | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-002 | Oct 19, 2009 | ⤷ Try a Trial | ⤷ Try a Trial |
Novartis | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-002 | Oct 19, 2009 | ⤷ Try a Trial | ⤷ Try a Trial |
Novartis | VOTRIENT | pazopanib hydrochloride | TABLET;ORAL | 022465-001 | Oct 19, 2009 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for VOTRIENT
See the table below for patents covering VOTRIENT around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Brazil | 0116452 | ⤷ Try a Trial | |
Canada | 2432000 | PYRIMIDINEAMINES COMME MODULATEURS DE L'ANGIOGENESE (PYRIMIDINEAMINES AS ANGIOGENESIS MODULATORS) | ⤷ Try a Trial |
Spain | 2324981 | ⤷ Try a Trial | |
South Korea | 100847169 | ⤷ Try a Trial | |
Austria | 430742 | ⤷ Try a Trial | |
Germany | 60138645 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VOTRIENT
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1343782 | 91710 | Luxembourg | ⤷ Try a Trial | 91710, EXPIRES: 20250614 |
1343782 | SPC025/2010 | Ireland | ⤷ Try a Trial | SPC025/2010: 20110401, EXPIRES: 20250613 |
1343782 | 10C0037 | France | ⤷ Try a Trial | PRODUCT NAME: PAZOPANIB; REGISTRATION NO/DATE: EU/1/110/628/001 20100614 |
1343782 | C300456 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: PAZOPANIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT, IN HET BIJZONDER PAZOPANIB HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/10/628/001-004 20100614 |
1343782 | 122010000038 | Germany | ⤷ Try a Trial | PRODUCT NAME: PAZOPANIB ODER EIN SALZ ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/10/628/001-004 20100614 |
1343782 | SPC/GB10/032 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: PAZOPANIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE; REGISTERED: UK EU 1/10/628/001 20100614; UK EU 1/10/628/002 20100614; UK EU 1/10/628/003 20100614; UK EU 1/10/628/004 20100614 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |